Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

Summary

The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19 pneumonia.

Timeline

Start

2020-10-31

Primary completion

2021-01-27

Completion

2021-01-27

Outcome

Outcome not reported

Stopped (Enrollment): “Study was withdrawn due to challenges in site recruitment and lack of patient enrollment”

Drugs

Indications